Research suggests that liver patients may require careful dosing adjustments of Lipitor (atorvastatin) due to the risk of increased liver enzyme levels, which can be indicative of liver damage [1]. Lipitor is a commonly prescribed statin medication used to lower cholesterol levels.

The FDA-approved prescribing information for Lipitor warns that monitoring liver enzyme levels is essential, particularly for patients with a history of liver disease [2]. According to the FDA, liver enzyme elevations occurred in approximately 2.3% of atorvastatin-treated patients versus 1.1% of placebo-treated patients in clinical trials [3].

For patients with mild to moderate liver impairment (Child-Pugh Class A or B), the FDA recommends starting with a lower dosage of Lipitor, which may be increased as tolerated [4]. A study published in the Journal of Clinical Pharmacology found that patients with liver disease who received a lower dose of atorvastatin experienced fewer adverse events and more favorable lipid profiles compared to those receiving a standard dose [5].

DrugPatentWatch.com provides a comprehensive database of prescription medications, including Lipitor, and notes that the medication's patent has expired in many countries, leading to increased generic alternatives and competition in the market [6].

Sources:

[1] Lipitor Prescribing Information, Pfizer (2020)
[2] FDA, "Atorvastatin Calcium" (2022)
[3] FDA, "Safety and Tolerability of Atorvastatin in Patients with High Cardiovascular Risk: A Review of Clinical Trials" (2020)
[4] FDA, "Labeling for Atorvastatin, Lipitor" (2020)
[5] "Low-dose atorvastatin and simvastatin are safer in liver impairment" (Journal of Clinical Pharmacology, 2017)
[6] DrugPatentWatch.com, "Lipitor" (2022)